ArticleInternational journal of pharmaceutics2025
Design of SLS 3D-printed pediatric combination printlets of lamivudine and tenofovir disoproxil fumarate by understanding the impact of formulation and process variables on flow, spectral, thermal and performance characteristics.
Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Addressing printability of poorly flowable drug by wet granulation: understanding interplays of formulation and process variables on critical quality attributes of sulfadiazine printlets.International journal of pharmaceutics · 2026Article
- Three-Dimensional Printing in Paediatrics: Innovative Technology for Manufacturing Patient-Centred Drug Delivery Systems.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Adherence to pediatric HIV therapy continues to be a challenge for achieving the desired therapeutic outcomes in children due to various factors, the primary one being the lack of availability of a dose-flexible pediatric combination formulation. The study thus aimed to create a pediatric-friendly combination of lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) printlets by examining how formulation and process variables interact within selective laser sintering (SLS) 3D printing technology. A Plackett-Burman screening design was used to pinpoint critical factors impacting product quality. Eight factors, encompassing both formulation and process parameters, were assessed to identify the main effects. These include the percentage of combination drug (30-40 %) in a 1:1 ratio, Kollicoat® IR (0-57 %), hydroxypropyl methyl cellulose (0-67 %), sucrose (0-67 %), and mannitol (0-57 %), surface (80-100 °C) and chamber temperature (60-80 °C), and laser scanning speed (250-300 mm/sec). The influence of these factors was examined in relation to seven responses: angle of repose, hardness, disintegration time, assay of 3TC, assay of TDF, and dissolution of 3TC and TDF at 10 min. The results showed that a 1:1 drug ratio with 40 % loading produced printlets meeting USP assay and dissolution standards. Surface temperature, KCIR amount, and laser scanning speed significantly influenced printlet performance (p < 0.05). Characterization techniques, including differential scanning calorimetry, X-ray diffraction, and near-infrared hyperspectral imaging, confirmed that both drugs were effectively incorporated in the printlets while maintaining stability and uniformity. Thus, by studying the interplay of variables and their outcomes alongside characterization studies, this research supports the use of SLS 3D printing as a promising method for developing pediatric-friendly combination antiviral therapies that enhance dosing flexibility and improve adherence potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.